ES2629751T3 - Derivados de pirazol novedosos - Google Patents

Derivados de pirazol novedosos Download PDF

Info

Publication number
ES2629751T3
ES2629751T3 ES14709590.5T ES14709590T ES2629751T3 ES 2629751 T3 ES2629751 T3 ES 2629751T3 ES 14709590 T ES14709590 T ES 14709590T ES 2629751 T3 ES2629751 T3 ES 2629751T3
Authority
ES
Spain
Prior art keywords
substituted
alkyl
alkoxy
cycloalkyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14709590.5T
Other languages
English (en)
Inventor
Uwe Grether
Atsushi KIMBARA
Matthias Nettekoven
Fabienne Ricklin
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2629751T3 publication Critical patent/ES2629751T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Un compuesto de fórmula (I)**Fórmula** en la que A1 es -CH- o nitrógeno; A2 es -CH- o nitrógeno; A3 es -(CH2)n- o -CH2C(O)-; R1 es alquilo, cicloalquilo, alcoxi o halógeno; R2 es alcoxi, pirrolidinilo sustituido o dihidropirrolilo sustituido, en el que pirrolidinilo sustituido y dihidropirrolilo sustituido son pirrolidinilo y dihidropirrolilo sustituidos con uno o dos sustituyentes independientemente seleccionados de halógeno, hidroxilo, hidroxialquilo, alcoxialquilo y alquilfurazanilalcoxi; R3 es fenilo, fenilo sustituido, furazanilo sustituido, piridinilo, piridinilo sustituido, dioxotietanilo, tetrahidrofuranilo, tetrazolilo sustituido o triazolilo sustituido, en el que fenilo sustituido, piridinilo sustituido y triazolilo sustituido son fenilo, piridinilo y triazolilo sustituidos con uno o dos sustituyentes independientemente seleccionados de alquilo, alcoxi, halógeno, haloalquilo, alquilsulfonilo y cicloalquilo, y en el que tetrazolilo sustituido y furazanilo sustituido son tetrazolilo y furazanilo sustituidos con un sustituyente seleccionado de alquilo, alcoxi, halógeno, haloalquilo, alquilsulfonilo y cicloalquilo; n es 1 o 2; siempre que A1 y A2 30 no sean ambos carbono al mismo tiempo; o una sal o éster farmacéuticamente aceptable del mismo; en la que "alquilo", solo o en combinación, es un grupo alquilo de cadena lineal o cadena ramificada con 1 a 8 átomos de carbono; "cicloalquilo", solo o en combinación, es un anillo cicloalquilo con 3 a 8 átomos de carbono; y "alcoxi", solo o en combinación, es un grupo de la fórmula alquil-O-.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
en presencia de R2H y una base;
(b) la reacción de un compuesto de fórmula (B)
imagen12
en presencia de R3-A3-X y una base;
(c) la reacción de un compuesto de fórmula (C)
imagen13
15 en presencia de MR1, un catalizador de paladio y una base;
(d) la reacción de un compuesto de fórmula (D)
imagen14
20 en presencia de MR1, un catalizador de paladio y una base;
en la que A1 a A3 y R1 a R3 son como se definen anteriormente, X es un grupo saliente y M es una especie de metal adecuadamente sustituida, como una especie de boro, borilo, trifluoro-borato o estannilo. 25 En la etapa (a), la base es por ejemplo DIEA.
La etapa (a) se lleva a cabo en particular ventajosamente en un disolvente inerte, tal como DMF. La etapa (a) se puede llevar a cabo convenientemente a 120 ºC. 30 En la etapa (b), la base es por ejemplo terc-butóxido, carbonato de cesio o carbonato de potasio.
La etapa (b) se lleva a cabo en particular ventajosamente en un disolvente inerte, como DMF o DMA. La etapa (b) se puede llevar a cabo convenientemente a 120 ºC.
35 En la etapa (c), el catalizador de paladio es por ejemplo acetato de paladio(II). La etapa (c) se lleva a cabo preferentemente en presencia de una fosfina, particularmente n-butil-di-adamantilfosfina.
12
imagen15
imagen16
imagen17
imagen18
imagen19
6-terc-butil-1-[(2-clorofenil)metil]-4-etoxi-1H-pirazolo[3,4-d]pirimidina
imagen20
5 El compuesto del título se sintetizó en analogía con los ejemplos 1c a 1f, usando 5-amino-1-[(2-clorofenil)metil]-1Hpirazol-4-carboxamida (CAN 106898-48-0), cloruro de pivaloílo y etanol como materiales de partida, y se aisló (15 mg) como un aceite incoloro; CLEM (área de pico UV, ESI) 83 %, 345,5 [MH+].
10 Ejemplo 6
6-terc-butil-1-[(2-cloro-4-fluorofenil)metil]-4-(3,3-difluoro-pirrolidin-1-il)-1H-pirazolo[3,4-d]pirimidina
a) 6-terc-butil-4-(3,3-difluoro-pirrolidin-1-il)-1H-pirazolo[3,4-d]pirimidina 15
imagen21
A una mezcla de 6-terc-butil-4-(3,3-difluoro-pirrolidin-1-il)-1-(4-metoxi-bencil)-1H-pirazolo[3,4-d]pirimidina (0,174 g, 0,43 mmol) y TFA (870 µl, 11,3 mmol) en DCM (3 ml) se le añadió ácido metanosulfónico (141 µl, 2,17 mmol). La
20 mezcla se agitó durante 1 hora a 0 ºC y durante 1,5 horas a temperatura ambiente. Después de esto, la mezcla se volvió básica con solución de hidróxido de sodio (2,5 ml, 25 %, enfriamiento) y se repartió entre agua y DCM. Se mezclaron las fases orgánicas, se secó con MgSO4, se filtró y se concentró a vacío. El residuo, 135 mg del compuesto del título como un sólido amarillo claro, se usó sin purificación adicional; CLEM (área de pico UV, ESI) 80 %, 282,5 [MH+].
25 b) 6-terc-butil-1-(2-cloro-4-fluoro-bencil)-4-(3,3-difluoro-pirrolidin-1-il)-1H-pirazolo [3,4-d]pirimidina
imagen22
30 A una solución de 6-terc-butil-4-(3,3-difluoro-pirrolidin-1-il)-1H-pirazolo[3,4-d]pirimidina (30 mg, 107 µmol) en acetona (1 ml) y DMF (2 ml) se le añadió 2-cloro-1-(clorometil)-4-fluoro-benceno (23 mg, 128 µmol) y carbonato de potasio (44 mg, 318 µmol). La mezcla se sometió a microondas durante 45 minutos a 120 ºC, se enfrió y se repartió entre agua y acetato de etilo. Se mezclaron las fases orgánicas, se secó por filtración sobre ChemElut®, y se concentró a vacío. El residuo se purificó por HPLC preparativa (Gemini NX, gradiente de agua/acetonitrilo), para proporcionar el
18
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
Ejemplo
CE50 de CB2 humano [µM] CE50 de CB1 humano [µM]
1
0,0048 >10
2
0,0033 >10
3
0,0051 >10
4
0,0042 >10
5
0,0255 >10
6
0,0059 >10
7
0,0011 >10
8
0,0054 >10
9
0,0005 >10
10
0,0007 0,3368
11
0,0187 >10
12
0,0016 1,5741
13
0,0196 >10
14
0,0013 >10
15
0,0009 >10
16
0,0006 >10
17
0.003 >10
18
0,0262 >10
19
0,0014 >10
20
0,0016 >10
21
0,0034 >10
22
0,0084 >10
23
0,0055 >10
24
0,0175 >10
25
0,0004 >10
26
0,0356 >10
27
0,0425 >10
28
0,0019 >10
29
0,0019 >10
30
0,0024 >10
31
0,0173 >10
32
0,0015 >10
33
0,0088 >10
34
0.005 >10
35
0,0133 >10
36
0,0014 >10
37
0,0172 >10
38
0,0160 >10
Ejemplo A
Los comprimidos recubiertos con película que contienen los siguientes ingredientes se pueden fabricar de manera convencional:
Ingredientes
Por comprimido
Núcleo:
Compuesto de fórmula (I)
10,0 mg 200,0 mg
Celulosa microcristalina
23,5 mg 43,5 mg
Lactosa hidratada
60,0 mg 70,0 mg
Povidona K30
12,5 mg 15,0 mg
Glicolato sódico de almidón
12,5 mg 17,0 mg
Estearato de magnesio
1,5 mg 4,5 mg
(Peso del núcleo)
120,0 mg 350,0 mg
Recubrimiento de película:
Hidroxipropilmetilcelulosa
3,5 mg 7,0 mg
Polietilenglicol 6000
0,8 mg 1,6 mg
Talco
1,3 mg 2,6 mg
Óxido de hierro (amarillo)
0,8 mg 1,6 mg
Dióxido de titanio
0,8 mg 1,6 mg
41
imagen45

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
ES14709590.5T 2013-03-07 2014-03-04 Derivados de pirazol novedosos Active ES2629751T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13158233 2013-03-07
EP13158233 2013-03-07
PCT/EP2014/054107 WO2014135507A1 (en) 2013-03-07 2014-03-04 Novel pyrazol derivatives

Publications (1)

Publication Number Publication Date
ES2629751T3 true ES2629751T3 (es) 2017-08-14

Family

ID=47827068

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14709590.5T Active ES2629751T3 (es) 2013-03-07 2014-03-04 Derivados de pirazol novedosos

Country Status (34)

Country Link
US (2) US9512132B2 (es)
EP (1) EP2964646B1 (es)
JP (2) JP6514119B2 (es)
KR (2) KR102217297B1 (es)
CN (1) CN105143220B (es)
AR (1) AR094978A1 (es)
AU (1) AU2014224784B2 (es)
BR (1) BR112015020795B1 (es)
CA (1) CA2897513C (es)
CL (1) CL2015002387A1 (es)
CR (1) CR20150447A (es)
CY (1) CY1118950T1 (es)
DK (1) DK2964646T3 (es)
EA (1) EA027935B1 (es)
ES (1) ES2629751T3 (es)
HR (1) HRP20170919T1 (es)
HU (1) HUE034831T2 (es)
IL (1) IL240327B (es)
LT (1) LT2964646T (es)
MA (1) MA38403A1 (es)
MX (1) MX363727B (es)
MY (1) MY176797A (es)
NZ (1) NZ710052A (es)
PE (1) PE20151539A1 (es)
PH (1) PH12015501843A1 (es)
PL (1) PL2964646T3 (es)
PT (1) PT2964646T (es)
RS (1) RS56148B1 (es)
SG (1) SG11201507168XA (es)
SI (1) SI2964646T1 (es)
TW (1) TWI609866B (es)
UA (1) UA118666C2 (es)
WO (1) WO2014135507A1 (es)
ZA (1) ZA201505073B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014224784B2 (en) * 2013-03-07 2018-03-08 F. Hoffmann-La Roche Ag Novel pyrazol derivatives
CN105121436B (zh) 2013-03-26 2018-07-27 豪夫迈·罗氏有限公司 新的吡啶衍生物
AU2014261585B2 (en) 2013-05-02 2018-03-08 F. Hoffmann-La Roche Ag Purine derivatives as CB2 receptor agonists
WO2014177527A1 (en) 2013-05-02 2014-11-06 F. Hoffmann-La Roche Ag Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
JP6441356B2 (ja) 2013-09-06 2018-12-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規トリアゾロ［４，５−ｄ］ピリミジン誘導体
CA2979534A1 (en) * 2015-03-13 2016-09-22 Abbvie Inc. (indazol-4-yl)hexahydropyrrolopyrrolones and method of use
WO2016191935A1 (en) * 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
CN109311886B (zh) 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
WO2017220516A1 (en) 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
WO2017220544A1 (en) 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
MX2018014684A (es) 2016-06-23 2019-02-28 Hoffmann La Roche Derivados de [1,2,3]triazolo[4,5-d]pirimidina con afinidad para el receptor de canabinoide de tipo 2.
US12504353B2 (en) 2019-03-25 2025-12-23 Nikon Corporation Cell manipulation device and cell manipulation method
JP2023541601A (ja) 2020-09-10 2023-10-03 プレシリックス・ナームローゼ・ベンノートシヤープ Ｆａｐに対する抗体フラグメント
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
CA3251753A1 (en) 2022-05-02 2023-11-09 Precirix N.V. PRE-TARGETTING
CN115246832B (zh) * 2022-06-15 2024-05-24 深圳湾实验室 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2980677A (en) * 1961-04-18 Certificate of correction
WO2001058869A2 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
DE10219435A1 (de) * 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
EP2211619A1 (en) 2007-10-18 2010-08-04 Merck Sharp & Dohme Corp. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
JP2015521652A (ja) 2012-07-04 2015-07-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ カンナビノイド受容体２アゴニストとしての新規アダマンチル誘導体
CN104837818B (zh) 2012-12-07 2017-07-14 霍夫曼-拉罗奇有限公司 可用作cb2激动剂的吡啶‑2‑酰胺
AU2013354115B2 (en) 2012-12-07 2017-10-05 F. Hoffmann-La Roche Ag Novel pyrazine derivatives as CB2 receptor agonists
SG10201800170YA (en) 2012-12-07 2018-02-27 Hoffmann La Roche Novel pyridine derivatives
PL2928868T3 (pl) 2012-12-07 2017-12-29 F.Hoffmann-La Roche Ag Pirydyno-2-amidy użyteczne jako agoniści cb2
AU2014224784B2 (en) * 2013-03-07 2018-03-08 F. Hoffmann-La Roche Ag Novel pyrazol derivatives

Also Published As

Publication number Publication date
US20150376192A1 (en) 2015-12-31
US9694012B2 (en) 2017-07-04
AR094978A1 (es) 2015-09-09
LT2964646T (lt) 2017-07-10
MX363727B (es) 2019-04-01
JP2019055986A (ja) 2019-04-11
HK1213258A1 (zh) 2016-06-30
SG11201507168XA (en) 2015-10-29
US9512132B2 (en) 2016-12-06
US20170035769A1 (en) 2017-02-09
CA2897513A1 (en) 2014-09-12
PL2964646T3 (pl) 2017-09-29
JP6514119B2 (ja) 2019-05-15
MA38403A1 (fr) 2017-11-30
EP2964646B1 (en) 2017-04-19
EP2964646A1 (en) 2016-01-13
CN105143220B (zh) 2018-06-22
KR102217297B1 (ko) 2021-02-22
AU2014224784B2 (en) 2018-03-08
HRP20170919T1 (hr) 2017-09-22
EA201591624A1 (ru) 2016-01-29
TWI609866B (zh) 2018-01-01
MX2015011534A (es) 2016-02-05
KR102369407B1 (ko) 2022-03-02
CA2897513C (en) 2021-03-16
TW201506023A (zh) 2015-02-16
IL240327A0 (en) 2015-09-24
CL2015002387A1 (es) 2016-03-04
PE20151539A1 (es) 2015-10-28
ZA201505073B (en) 2016-07-27
PT2964646T (pt) 2017-06-29
EA027935B1 (ru) 2017-09-29
PH12015501843B1 (en) 2015-12-07
AU2014224784A1 (en) 2015-07-23
HUE034831T2 (en) 2018-03-28
MY176797A (en) 2020-08-21
DK2964646T3 (en) 2017-07-10
BR112015020795B1 (pt) 2022-08-16
KR20210019578A (ko) 2021-02-22
CR20150447A (es) 2015-10-08
SI2964646T1 (sl) 2017-08-31
NZ710052A (en) 2020-09-25
UA118666C2 (uk) 2019-02-25
JP2016510054A (ja) 2016-04-04
BR112015020795A2 (pt) 2017-07-18
IL240327B (en) 2019-01-31
RS56148B1 (sr) 2017-11-30
CY1118950T1 (el) 2018-01-10
PH12015501843A1 (en) 2015-12-07
KR20150126355A (ko) 2015-11-11
CN105143220A (zh) 2015-12-09
WO2014135507A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
ES2629751T3 (es) Derivados de pirazol novedosos
ES2587903T3 (es) Compuestos de imidazolidinadiona y sus usos
KR101904632B1 (ko) 2,4-이치환 페닐-1,5-디아민 유도체, 이의 응용, 및 이로 제조한 약물 조성물
ES2585221T3 (es) Un proceso para la preparación de 6-(7-((1-aminociclopropil)metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1-naftamida y productos intermedios sintéticos de la misma
AU2016204432B2 (en) Process for making benzoxazepin compounds
DK3129374T3 (en) (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER
DK2991984T3 (en) PALLADIUM-CATALYST COUPLING OF PYRAZOLAMIDES
JP2013504543A5 (es)
AU2016370743A1 (en) Bipyrazolyl derivatives useful for the treatment of autoimmune diseases
CA2958625A1 (en) Crystal of pyrrole derivative and method for producing the same
CA3251124A1 (en) 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE
BR112013023480B1 (pt) Composto heterocíclico saturado contendo nitrogênio, seu uso e composição farmacêutica
EA021439B1 (ru) Хиназолиновые соединения
EP2252599A1 (en) Triazole amide derivatives for use in therapy
WO2006126718A1 (ja) ピラゾロピリミジン誘導体
EP2307401A2 (fr) Derives anticancereux de 4-oxo-1,4-dihydro-quinoline, leur preparation et leur application en therapeutique
EP1092720B1 (en) Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof
ES2485492T3 (es) Derivados de di(hetero)arilciclohexano, su preparación, su uso y composiciones farmacéuticas que los comprenden
US9969735B2 (en) Process for making tricyclic lactam compounds
KR20220097438A (ko) 암, 자가면역, 및 염증성 질환의 치료를 위한 다이하이드로오로테이트 데하이드로게나제(dhodh) 억제제로서의 플루오르화 퀴놀린 및 퀴녹살린 유도체
AU2024289347A1 (en) Nmt inhibitor, and preparation method therefor and use thereof
HK40037319A (en) Process for making tricyclic lactam compounds
ES2527011T3 (es) Derivados de piperazina para bloquear canales de calcio Cav2.2
CN104151278B (zh) 1-苯基-2,3-萘二羧酸酐及其衍生物的合成方法
Khlebnikov Fe (II)/Et3N-Relay-catalyzed domino reaction of isoxazoles with imidazolium salts in the synthesis of methyl 4-imidazolylpyrrole-2-carboxylates, its ylide and betaine derivatives